Volume 117, Issue 4 p. 647-652
Free Access

Lack of anticonvulsant tolerance and benzodiazepine receptor down regulation with imidazenil in rats

Adriano Zanotti

Adriano Zanotti

Fidia Research Laboratories, Abano, Italy

Search for more papers by this author
Roberta Mariot

Roberta Mariot

Fidia Research Laboratories, Abano, Italy

Search for more papers by this author
Angelo Contarino

Angelo Contarino

Dipartmento di Farmacologia, Universita di Padova, Padova, Italy

Search for more papers by this author
Maria Lipartiti

Maria Lipartiti

Dipartmento di Farmacologia, Universita di Padova, Padova, Italy

Search for more papers by this author
Pietro Giusti

Pietro Giusti

Dipartmento di Farmacologia, Universita di Padova, Padova, Italy

Department of Pharmacology, Fidia Research Laboratories, Abano, Italy

Search for more papers by this author
First published: February 1996
Citations: 13

Abstract

  • 1

    Development of anticonvulsant tolerance and benzodiazepine (BZD) receptor down-regulation has been reported to occur upon chronic administration of conventional BZDs. We compared the effect of chronic treatment with imidazenil, a new BZD partial agonist, and diazepam in rats.

  • 2

    After acute administration, imidazenil was more potent though less effective than diazepam in protecting from bicuculline-induced seizure. The time-course analysis of two peak equieffective doses of imidazenil (2.5 μmol kg−1 p.o.) and diazepam (35 μmol kg−1, p.o.) showed a longer lasting action of the former drug.

  • 3

    The anticonvulsant efficacy of diazepam (35 μmol kg−1, p.o.) was reduced in rats given chronic diazepam (35 μmol kg−1, p.o., 3 times a day for 8–15 days). No tolerance to imidazenil (2.5 μmol kg−1, p.o.) was apparent after 130-day administration with imidazenil (2.5 μmol kg−1, p.o., 3 times a day).

  • 4

    Plasma levels of imidazenil and diazepam, assessed 30 min after administration, were not changed in chronically treated animals.

  • 5

    In rats made tolerant to diazepam, the maximum number of [3H]-flumazenil binding sites were reduced in both cerebral cortex (−36%) and cerebellum (−42%). No changes in [3H]-flumazenil binding were found in chronic imidazenil-treated rats.

  • 6

    Specific [3H]-flumazenil binding in vivo was decreased in the forebrain of chronic diazepam- but not of chronic imidazenil-treated animals.

  • 7

    These data indicate that imidazenil possesses a very low tolerance potential to its anticonvulsant activity and does not affect BZD receptor density even after prolonged administration.